First Participant Dosed in Phase 1 Trial of Tmunity’s CAR T-cell Therapy in Solid Tumors

First Participant Dosed in Phase 1 Trial of Tmunity’s CAR T-cell Therapy in Solid Tumors
The first participant has been dosed in a Phase 1 clinical trial evaluating Tmunity Therapeutics' CAR T-cell therapy, CART-TnMUC1, in people with certain solid tumors, including ovarian cancer, that are positive for the TnMUC1 protein. The open-label trial (NCT04025216), which is still recruiting, is expected to enroll about 80 people with previously treated cancers that express TnMUC1. Participants are being enrolled at The Angeles Clinic and Research Institute in California and the Hospital of the University of Pennsylvania. T-cells are immune cells that are capable of killing cancer cells. When tumors do develop, it essentially means that the cancer cells have found ways to evade destruction by T-cells. Chimeric antigen receptor (CAR) T-cells are T-cells that are modified in a lab such that they have extra receptors that help them identify and kill the tumor cells. Typically, CAR T-cell therapy involves taking T-cells from a cancer patient, modifying them in the lab, and putting them back in the patient's body to fight the tumor. While these therapies have shown promise in certain blood cancers, they have generally not been very effective when tested in solid tumors. MUC1 is a glycoprotein — a protein with sugar molecules attached to it — that is normally produced by the cells that line many glands in the body. When these cells become cancerous, however, they tend to instead express an altered version of the protein — TnMUC1. CART-TnMUC1 is a CAR T-cell therapy in which the cells have been modified with a receptor specific to TnMUC1. The idea behind the therapy is to target the killing action of the T-cells toward this altered version of the protein and, by extension, the cancer cells. The modified receptor also includes a co-stimulatory regio
Subscribe or to access all post and page content.